drugset / Trial / NCT07190885
A Pharmacokinetic Study of YN001 in Healthy Participants
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, single-center, open-label study designed to evaluate the pharmacokinetics (PK), safety, and immunogenicity following a single dose administration in healthy adult volunteers.
Timeline
- Start
- 2025-11-18
- Primary completion
- 2026-09
- Completion
- 2026-09
Outcome
Outcome not reported
Stopped: “The study was suspended at the request of the Sponsor.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | YN001 | Unknown | 20 mg | Intravenous |
| Subject | YN001 | Unknown | 40 mg | Intravenous |
Indications
No indication recorded.